Karman Holdings Inc.
KRMNKarman Holdings Inc. (KRMN) is a company focused on providing innovative solutions in the healthcare and wellness sectors. It develops and markets various health-related products and services aimed at improving health outcomes and enhancing quality of life. The company's operations often include product development, distribution, and strategic partnerships within the health and wellness industry.
Company News
SpaceX's IPO on Nasdaq (ticker SPCX) has validated the commercial space sector at scale and triggered investor interest in public launch companies. Rocket Lab (RKLB) is positioned as the leading alternative, with record Q1 2026 revenue of $200.3M, a $2.2B+ backlog, and its Neutron medium-lift rocket expected to debut in 2026 as a potential Falcon...
Two space and defense companies are converting strong backlogs into revenue growth amid rising global defense spending. Karman (KRMN) reported record Q1 2026 revenue of $151M (+51% YOY) with a $1B+ backlog, though its stock has fallen 40% YTD and trades at a high P/E of ~200. AeroVironment (AVAV) boasts a $1.1B funded backlog and $4.6B in YTD awa...
SpaceX's anticipated $75 billion IPO at a $1.75 trillion valuation is reshaping the space sector and creating investment opportunities across publicly traded space companies. Starfighters Space announced a partnership with Mu-G Technologies to respond to a NASA RFI for commercial microgravity services, while other space sector companies are benef...
Karman, a defense company that went public in February 2025 at $22/share and peaked at $115 in January 2026, has dropped 40% but shows strengthening fundamentals. Q1 2026 results exceeded expectations with 51% YOY revenue growth to $151.2M and doubled adjusted EPS. The company raised full-year guidance, boasts a $1B backlog (61% YOY growth), and ...
Karman Space & Defense (KRMN) stock fell 6.8% despite beating earnings expectations with $151.2M in sales (vs. $150.2M expected) and $0.11 EPS. The company reported 51% YoY sales growth, reversed prior losses to profitability, and raised 2026 guidance to $720-735M revenue. However, the stock remains expensive at 17x sales and 468x earnings.
